Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease
Autor: | Bruce G. Wolff, Hongzhi Zou, David A. Ahlquist, Douglas W. Mahoney, W J Sandborn, William R. Taylor, Thomas C. Smyrk, Steven H. Itzkowitz, Tracy C. Yab, F. T. Nazer Hussain, Edward V. Loftus, John B. Kisiel, David T. Rubin, Megan Garrity-Park |
---|---|
Rok vydání: | 2013 |
Předmět: |
Adult
Genetic Markers Male medicine.medical_specialty Candidate gene Vimentin medicine.disease_cause Inflammatory bowel disease Gastroenterology Feces Predictive Value of Tests Internal medicine Biomarkers Tumor medicine Humans Pharmacology (medical) Aged Hepatology biology business.industry Cancer DNA Neoplasm Middle Aged Inflammatory Bowel Diseases medicine.disease Ulcerative colitis digestive system diseases Dysplasia Genetic marker biology.protein Female KRAS Colorectal Neoplasms business |
Zdroj: | Alimentary Pharmacology & Therapeutics. 37:546-554 |
ISSN: | 0269-2813 |
Popis: | SummaryBackground Current approaches to the detection of colorectal neoplasia associated with inflammatory bowel disease (IBD-CRN) are suboptimal. Aim To test the feasibility of using stool assay of exfoliated DNA markers to detect IBD-CRN. Methods This investigation comprised tissue and stool studies. In the tissue study, gene sequencing and methylation assays were performed on candidate genes using tissue DNA from 25 IBD-CRNs and from 25 IBD mucosae without CRN. Mutations on p53, APC, KRAS, BRAF or PIK3CA genes were insufficiently informative, but several aberrantly methylated genes were highly discriminant. In the stool study, we evaluated candidate methylated genes (vimentin, EYA4, BMP3, NDRG4) in a prospective blinded study on buffered stools from 19 cases with known IBD-CRN and 35 age- and sex-matched IBD controls without CRN. From stool-extracted DNA, target genes were assayed using quantitative allele-specific real-time target and signal amplification method. Results IBD-CRN cases included 17 with ulcerative colitis (UC) and two with Crohn's disease (CD); nine had cancer and 10 had dysplasia. Controls included 25 with UC and 10 with CD. Individually, BMP3, vimentin, EYA4 and NDRG4 markers showed high discrimination in stools with respective areas under the ROC curve of 0.91, 0.91, 0.85 and 0.84 for total IBD-CRN and of 0.97, 0.97, 0.95 and 0.85 for cancer. At 89% specificity, the combination of BMP3 and mNDRG4 detected 9/9 (100%) of CRC and 80% of dysplasia, 4/4 (100%) of high grade and 4/6 (67%) of low grade. Conclusion These findings demonstrate the feasibility of stool DNA testing for non-invasive detection of colorectal neoplasia associated with inflammatory bowel disease. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |